secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0000950170-22-021219
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences Q3 net loss narrows to $64.9M, cash $1.19B, ARC-10 amended to compare domvanalimab vs pembro
--------------------------------------------------------------------------------

- Q3 revenue $33.6M (up from $9.5M); net loss $64.9M vs $78.0M prior year.
- Cash and securities $1.19B as of Sep 30, 2022, funding operations into 2026.
- ARC-10 Phase 3 amended: domvanalimab+zimberelimab vs pembrolizumab, no chemo arm, OS primary endpoint, n=600.
- ARC-7 topline data on track for Q4 2022; presentation planned at 2023 medical conference.
- Initiated ARC-20 Phase 1/1b for HIF-2a inhibitor AB521 in cancer patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/0000950170-22-021219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/rcus-20221102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer